Beyond the Injection
One of the biggest barriers to GLP-1 therapy adoption has been the requirement for self-injection. Many patients, despite understanding the benefits, are reluctant to commit to weekly subcutaneous injections. Oral semaglutide (Rybelsus) was the first oral GLP-1 receptor agonist approved in Canada, but its initial formulation had limitations — it needed to be taken on an empty stomach with minimal water, and its bioavailability was significantly lower than the injectable form.
Next-Generation Oral Formulations
Novo Nordisk's high-dose oral semaglutide (25mg and 50mg) has shown results that rival the injectable version. In the OASIS-1 trial, oral semaglutide 50mg achieved 17.4% weight loss at 68 weeks — comparable to injectable Wegovy. This represents a potential game-changer for patients who prefer pills over needles.
Other companies are developing oral GLP-1 formulations using novel absorption-enhancing technologies. Pfizer's danuglipron, an oral small-molecule GLP-1 agonist, takes a different approach entirely — it doesn't require the absorption enhancers that semaglutide needs, potentially allowing more flexible dosing.
Canadian Access and Coverage
Rybelsus is currently available in Canada, though coverage varies by province and insurance plan. The higher-dose formulations are expected to receive Health Canada approval in 2026. Cost remains a significant barrier — oral semaglutide is priced similarly to the injectable form, at approximately $300-400 CAD per month without insurance.
The Convenience Factor
For many patients, the shift from weekly injection to daily pill represents a meaningful improvement in quality of life. Early adherence data suggests that patients are more likely to stay on oral GLP-1 therapy long-term compared to injectable forms, which could translate to better real-world outcomes.
